Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021:175:281-318.
doi: 10.1007/10_2017_32.

Recombinant Proteins and Monoclonal Antibodies

Affiliations
Review

Recombinant Proteins and Monoclonal Antibodies

Roy Jefferis. Adv Biochem Eng Biotechnol. 2021.

Abstract

The human genome has become a subject of public interest, whilst the proteome remains the province of specialists. Less appreciated is the human glycoprotein (GP) repertoire (proteoglycome!); however, some 50% of open reading frame genes encode for proteins (P) that may accept the addition of N-linked and/or O-linked sugar chains (oligosaccharides). It is established that the attachment of defined oligosaccharide structures impacts mechanisms of action (MoAs), pharmacokinetics, pharmacodynamics, etc., and is a critical quality attribute (CQA) for recombinant GP therapeutics. The oligosaccharide structure attached at a given site may exhibit structural heterogeneity, and individual structures (glycoforms) may modulate MoAs. The biopharmaceutical industry is challenged, therefore, to produce recombinant GP therapeutics that have structural fidelity to the natural (endogenous) molecule, in non-human cells. Multiple production platforms have been developed that, in addition to the natural glycoform, may produce unnatural glycoforms, including sugar residues that can be immunogenic in human subjects. Following a general introduction to the field, this review discusses glycosylation of recombinant monoclonal antibodies (mAbs), the contribution of glycoforms to MoAs and the development of customised mAb therapeutic glycoforms to optimise MoAs for individual disease indications.

Keywords: Critical quality attributes; Glycoforms; Glycoproteins; IgG subclasses; Mechanisms of action; Oligosaccharides; Recombinant antibody therapeutics.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Gupta SK, Bhandari B, Shrestha A, Biswal BK, Palaniappan C, Malhotra SS, Gupta N (2012) Mammalian zona pellucida glycoproteins: structure and function during fertilization. Cell Tissue Res 349(3):665–678 - PubMed - DOI
    1. Drickamer K, Taylor ME (2015) Recent insights into structures and functions of C-type lectins in the immune system. Curr Opin Struct Biol 34:26–34 - PubMed - PMC - DOI
    1. Monticelli M, Ferro T, Jaeken J, Dos Reis Ferreira V, Videira PA (2016) Immunological aspects of congenital disorders of glycosylation (CDG). J Inherit Metab Dis 39:765–780 - PubMed - DOI
    1. Laine RA (1994). Glycobiology 4(6):759–767 - PubMed - DOI
    1. Higel F, Seidl A, Sörgel F, Friess W (2016) N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur J Pharm Biopharm 100:94–100 - PubMed - DOI

MeSH terms

LinkOut - more resources